2-Amino-6-(benzylthio)purine is a purine derivative that has been studied for its potential biological activity. It has been shown to exhibit anti-inflammatory and anti-cancer properties. The synthesis of this compound typically involves the reaction of 2-amino-6-chloropurine with benzyl mercaptan in the presence of a base. Research on this compound is motivated by its potential therapeutic applications and its unique structural features that may contribute to its biological activity.'
| ID Source | ID |
|---|---|
| PubMed CID | 74644 |
| CHEMBL ID | 138342 |
| CHEBI ID | 79781 |
| SCHEMBL ID | 2115655 |
| Synonym |
|---|
| z89y54iwij , |
| unii-z89y54iwij |
| sri 702 |
| nsc-15747 |
| purine, 2-amino-6-(benzylthio)- |
| 6-benzylthioguanine |
| benzythioguanine |
| 1h-purin-2-amine, 6-[(phenylmethyl)thio]- |
| purine, 2-amino-6-benzylthio)- |
| 2-amino-6-(benzylthio)purine |
| nsc15747 |
| 1874-58-4 |
| BTG , |
| einecs 217-502-2 |
| 1h-purin-2-amine, 6-((phenylmethyl)thio)- |
| benzylthioguanine |
| nsc 15747 |
| 6-((phenylmethyl)thio)-1h-purin-2-amine |
| 2-amino-6-benzyl-mp |
| ai3-50232 |
| 2-amino-6-benzylmercaptopurine |
| purine, 2-amino-6-benzylthio- |
| 2-amino-6-benzylthiopurine |
| NCGC00161967-01 |
| smr000543454 |
| MLS001214753 |
| chebi:79781 , |
| CHEMBL138342 |
| purine, 2-amino-6-benzylmercapto |
| 6-benzylsulfanyl-9h-purin-2-amine |
| 6-benzylsulfanyl-7h-purin-2-amine |
| STL056187 |
| 6-(benzylsulfanyl)-9h-purin-2-amine |
| HMS2877E04 |
| AKOS005708945 |
| 9h-purin-2-amine,6-[(phenylmethyl)thio]- |
| 9h-purin-2-amine, 6-((phenylmethyl)thio)- |
| 2-amino-6-benzylmercapto-9h-purine |
| JQMGATKUPCKDEG-UHFFFAOYSA-N |
| SCHEMBL2115655 |
| DTXSID40172053 |
| 6-(benzylthio)-9h-purin-2-amine |
| 6-[(phenylmethyl)thio]-1h-purin-2-amine |
| Q27148915 |
| Class | Description |
|---|---|
| thiopurine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 17.7828 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 20.5878 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| 67.9K protein | Vaccinia virus | Potency | 12.5893 | 0.0001 | 8.4406 | 100.0000 | AID720579 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 0.6310 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 46.3366 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 4.4668 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 3.1623 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| protein binding | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| follicle-stimulating hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| Golgi lumen | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| follicle-stimulating hormone complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| pituitary gonadotropin complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID32855 | Inhibitory activity against alkyl transferase in HT-29 cell-free extracts; inactive | 1992 | Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23 | Structural features of substituted purine derivatives compatible with depletion of human O6-alkylguanine-DNA alkyltransferase. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.87) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||